Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,000.79 USD
-5.08 (-0.51%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $1,001.51 +0.72 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,000.79 USD
-5.08 (-0.51%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $1,001.51 +0.72 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up
by Zacks Equity Research
Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.
Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
by Arpita Dutt
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
by Zacks Equity Research
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback
by Arpita Dutt
Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.
Regeneron's Evinacumab Gets Breakthrough Therapy by FDA
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.
4 FDA Decisions to Watch Out for in Apr 2017
by Arpita Dutt
Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.
Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
by Arpita Dutt
Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.
Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.
What are Sanofi's (SNY) Strengths and Challenges in 2017?
by Zacks Equity Research
We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
by Arpita Dutt
The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.
Amgen's Repatha Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).
Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
by Zacks Equity Research
Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
A Trip to 8-Year Bull Run: What's Up, What's Down
by Sweta Killa
While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.
5 FDA Decisions to Watch Out for in Mar 2017
by Arpita Dutt
Companies like Merck (MRK) are awaiting key FDA decisions this month.
Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported fourth-quarter 2016 loss of $1.86 per share, wider than both the Zacks Consensus Estimate of a loss of $1.64 and the year-ago loss of $1.02.
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
by Zacks Equity Research
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
by Arpita Dutt
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.
Regeneron (REGN) Q4 Earnings Misses Estimates
by Ekta Bagri
Regeneron???s fourth-quarter 2016 earnings missed expectations
Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
by Zacks Equity Research
Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.